FAP and breast cancer: For instance, in PET (positron emission tomography)/CT (computed tomography), 68Ga-FAPI-04, one of the quinoline-based FAP inhibitors (FAPIs) developed by the University Hospital Heidelberg, has become a more promising tracer that can discriminate cancerous lesions more accurately compared with 18F-FDG in a cohort of 48 BC patients.